



Minimally invasive **allogeneic bone-cell technologies** & enriched protein solution



Clinical-stage product candidates with proven **efficacy and acceptable safety profile** addressing large and growing markets with high unmet medical needs



Strong **IP portfolio, proprietary cell therapy manufacturing process and facility** and know-how

MISSION

We aim to be a leading biotech company providing unique, innovative products addressing high unmet medical needs in the fields of orthopaedics and bone diseases.

VALUE DRIVERS

- Off-the-shelf solutions
- Large, underserved patient populations
- Later-stage clinical validation
- Competitive, scalable, proprietary cell therapy manufacturing process


KEY FACTS

- Clinical pipeline across 3 indications
- Product candidates entering Phase II/III development
- Strong IP portfolio, proprietary cell therapy manufacturing process and know-how

AMBITIONS

- Advancing innovation in orthopaedic care
- Progressing the pipeline through Phase II/III development towards commercialization
- Partnerships for co-development and commercialization

CLINICAL PIPELINE



ADVANCING INNOVATION IN ORTHOPAEDIC CARE

2 PRODUCTS ENTERING PHASE II/III END 2019

ALLOB **BONE CELL THERAPY**

- Differentiated, active bone-forming cells
- Allogeneic (from healthy donor bone marrow)
- Injectable (minimally invasive)
- Economical, large-scale manufacturing
- Off-the-shelf (ready to use)
- Market :
 - Delayed-union fractures (~ 700K patients p.a.)
 - Spinal fusion procedures (~ 500K patients p.a.)

JTA-004 **ENRICHED PROTEIN SOLUTION**

- Patented composition of 3 active substances
- Convenient, single injection
- Analgesic & lubricating properties
- Better pain reduction vs market leader
- Simple manufacturing process
- Market :
 - Symptomatic knee osteoarthritis (~ 27M patients p.a. in EU/USA/JAP)

Bone Therapeutics is listed on Euronext Brussels and Euronext Paris with the ticker symbol "BOTHE" and ISIN code BE0974280126.

Analyst coverage
 Hugo Solvet (Bryan, Garnier & Co)
 Sandra Cauwenberghs (KBC Securities)
 Arsene Guekam (Kepler Cheuvreux)

Headquarters and manufacturing
 Rue Auguste Piccard 37
 6041 Gosselies - Belgium
 Phone : +32 (0) 71 12 10 00

Contact : info@bonetherapeutics.com

WWW.BONETHERAPEUTICS.COM